PI3K inhib 
Welcome,         Profile    Billing    Logout  
 67 Companies  59 Products   59 Products   344 Diseases   343 Trials   12261 News 


«12...136137138139140141142143144145146...229230»
  • ||||||||||  Journal:  Role of the PI3K and Hippo pathways in follicle activation after grafting of human ovarian tissue. (Pubmed Central) -  Nov 25, 2020   
    This study supports the hypothesis that follicle activation may occur as an early event after transplantation, with follicle growth and death both contributing to the burnout phenomenon. This is the first time that the effectors of the PI3K and Hippo pathways have been investigated in grafted human ovarian tissue and their role in burnout documented.
  • ||||||||||  Copiktra (duvelisib) / Secura Bio, Yakult Honsha
    [VIRTUAL] Cutaneous Toxicities of PI3K Inhibitors: A Series of Two Cases and Review of the Literature () -  Nov 25, 2020 - Abstract #FCDC2020FCDC_210;    
    Though one patient was able to later continue on therapy, both patients experienced recurrence with repeat exposure to duvelisib, establishing a notable temporal correlation. Thus, these cases contribute a novel presentation of adverse reactions to PI3K inhibitors to existing literature.
  • ||||||||||  Journal:  Ethanol-induced CYP2E1 Expression is Reduced by Lauric Acid via PI3K Pathway in HepG2 Cells. (Pubmed Central) -  Nov 22, 2020   
    However, there was no significant difference in NFκB pathway, in which the normalised NFκB p105 (Ser933) phosphorylation remained constant in any treatment conditions in this study. This suggests that ethanol induced CYP2E1 expression by activating PI3K p85 (Tyr458) pathway, but not the NFκB p105 (Ser933) pathway in HepG2 cells.
  • ||||||||||  Herceptin (trastuzumab) / Roche, AUM302 / AUM Biosci
    Preclinical, Journal:  Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. (Pubmed Central) -  Nov 22, 2020   
    The combination of trastuzumab and IBL-302 significantly increased the anti-proliferative effect in HER2+ breast cancer cell line, and matched trastuzumab-resistant line, relative to testing either drug alone. We thus believe that the novel PIM and PI3K/mTOR inhibitor, IBL-302, represents an exciting new potential treatment option for breast cancer, and that it should be considered for clinical investigation.
  • ||||||||||  buparlisib (BKM120) / Novartis, Adlai Nortye
    Journal:  Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy. (Pubmed Central) -  Nov 22, 2020   
    Targeted therapies, especially those inhibiting PI3K, display promising effects in multiple chordoma cell line and xenograft models. Nevertheless, the limited effects of PI3K, EGFR, and CDK targeting agents in other models reveal the presence of resistance mechanisms, which motivates future research to both identify biomarkers of response and develop combination therapies.
  • ||||||||||  quercetin (LY294002) / Eli Lilly
    Journal, IO Biomarker:  CCN5 inhibits proliferation and promotes apoptosis of oral squamous cell carcinoma cells. (Pubmed Central) -  Nov 21, 2020   
    Further, LY294002, a PI3K/AKT antagonist, was employed to explore the mechanism underlying the effects of CCN5 in the regulation of OSCC...Finally, xenograft analysis showed that CCN5 represses tumorigenesis of OSCC cells. These findings together suggest that CCN5 functions as a tumor suppressor for OSCC cell development through inactivation of PI3K/AKT signaling pathway, providing a potential candidate for OSCC therapy.
  • ||||||||||  Clinical, Review, Journal:  Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? (Pubmed Central) -  Nov 19, 2020   
    Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold.
  • ||||||||||  Preclinical, Journal:  Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. (Pubmed Central) -  Nov 19, 2020   
    Addition of chloroquine that suppressed autophagic flux to 2D GBM cultures increased CBD-induced cell death, presenting proof for the protective autophagy...Suppression of JNK activation partially reduced CBD-induced cell death in 3D GBM cultures. In contrast, co-treatment of CBD-targeted cells with inhibitors of PI3K-AKT-NF-κB, IKK-NF-κB or JAK2-STAT3 pathways killed surviving GBM cells in both 2D and 3D cultures, potentially improving the therapeutic ratio of GBM.